FindTrial
Sign In

Safety and efficacy of immunosuppressive regimen combined with mTOR inhibitors in patients with renal insufficiency before liver transplantation

Safety and efficacy of immunosuppressive regimen combined with mTOR inhibitors in patients with renal insufficiency before liver transplantation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041537
Enrollment
Unknown
Registered
2020-12-28
Start date
2020-12-30
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplant

Interventions

trial group:immunosuppressive regimen combined with mTOR inhibitors

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with preoperative renal insufficiency after orthotopic liver transplantation; donor and recipient age > 18 years old and < 70 years old; donors and recipients are Han nationality; follow-up period is more than 1 year.

Exclusion criteria

Exclusion criteria: Living donor liver transplantation; hyperlipidemia before liver transplantation; massive hemorrhage during operation; poor follow-up compliance.

Design outcomes

Primary

MeasureTime frame
blood chemistry;Immune function test;acute rejection;—

Secondary

MeasureTime frame
uncontrolled hyperlipidemia or tumor;—

Countries

China

Contacts

Public ContactJinyan Zhang

Shanghai General Hospital

zhang_jyz@yeah.net+86 13301765615

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026